References
- United States Renal Data System. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2014. USRDS annual data report: an overview of the epidemiology of kidney disease in the United States; 2014.
- Genovese G, Friedman DJ, Ross MD, Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010 Aug 13; 329( 5993): 841– 5.
- Tzur S, Rosset S, Shemer R, Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet. 2010 Sep; 128( 3): 345– 50.
- Freedman BI. APOL1 and kidney disease: new insights leading to novel therapies. Am J Kidney Dis. 2015 Jul; 66( 1): 9– 11.
- Palmer ND, Freedman BI. APOL1 and Progression of Nondiabetic Nephropathy. J Am Soc Nephrol. 2013 Sep; 24( 9): 1344– 6.
- Lipkowitz MS. Apolipoprotein L1: from obscurity to consistency to controversy. Kidney Int. 2015 Jan; 87( 1): 14– 7.
- Weckerle A, Snipes JA, Cheng D, Characterization of circulating APOL1 protein complexes in African Americans. J Lipid Res. 2016 Jan; 57( 1): 120– 30.
- Samanovic M, Molina-Portela MP, Chessler AD, Burleigh BA, Raper J. Trypanosome lytic factor, an antimicrobial high-density lipoprotein, ameliorates Leishmania infection. PLoS Pathog. 2009 Jan; 5( 1): e1000276.
- Mukamal KJ, Tremaglio J, Friedman DJ, APOL1 Genotype, Kidney and Cardiovascular Disease, and Death in Older Adults. Arterioscler Thromb Vasc Biol. 2016 Feb; 36( 2): 398– 403.
- Foster MC, Coresh J, Fornage M, APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol. 2013 Sep; 24( 9): 1484– 91.
- Bentley AR, Divers J, Shriner D, APOL1 G1 genotype modifies the association between HDLC and kidney function in African Americans. BMC Genomics. 2015 May 30; 16: 421.
- Friedman DJ, Kozlitina J, Genovese G, Jog P, Pollak MR. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol. 2011 Nov; 22( 11): 2098– 2105.
- Freedman BI, Langefeld CD, Murea M Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans. Nephrol Dial Transplant. 2011; 26: 3805– 10.
- Gutierrez OM, Judd SE, Irvin MR, APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans. Nephrol Dial Transplant. 2016 Apr; 31( 4): 602– 8.
- Bentley AR, Doumatey AP, Chen G, Variation in APOL1 Contributes to Ancestry-Level Differences in HDLc-Kidney Function Association. Int J Nephrol. 2012; 2012: 748984.
- Detrano R, Guerci AD, Carr JJ, Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008 Mar 27; 358( 13): 1336– 45.
- Budoff MJ, McClelland RL, Chung H, Reproducibility of coronary artery calcified plaque with cardiac 64-MDCT: the Multi-Ethnic Study of Atherosclerosis. AJR Am J Roentgenol. 2009 Mar; 192( 3): 613– 7.
- Budoff MJ, Young R, Lopez VA, Progression of coronary calcium and incident coronary heart disease events: MESA Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol. 2013 Mar 26; 61( 12): 1231– 9.
- Bild DE, Detrano R, Peterson D, Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis MESA. Circulation. 2005 Mar 15; 111( 10): 1313– 20.
- Lee TC, O'Malley PG, Feuerstein I, Taylor AJ. The prevalence and severity of coronary artery calcification on coronary artery computed tomography in black and white subjects. J Am Coll Cardiol. 2003 Jan 1; 41( 1): 39– 44.
- Freedman BI, Hsu FC, Langefeld CD, The impact of ethnicity and sex on subclinical cardiovascular disease: the Diabetes Heart Study. Diabetologia. 2005 Dec; 48( 12): 2511– 8.
- Carnethon MR, Bertoni AG, Shea S, Racial/Ethnic differences in subclinical atherosclerosis among adults with diabetes: the multiethnic study of atherosclerosis. Diabetes Care. 2005 Nov; 28( 11): 2768– 70.
- Wassel CL, Pankow JS, Peralta CA, Choudhry S, Seldin MF, Arnett DK. Genetic ancestry is associated with subclinical cardiovascular disease in African-Americans and Hispanics from the multi-ethnic study of atherosclerosis. Circ Cardiovasc Genet. 2009 Dec; 2( 6): 629– 36.
- Divers J, Palmer ND, Lu L, Admixture mapping of coronary artery calcified plaque in African Americans with type 2 diabetes. Circ Cardiovasc Genet. 2013 Feb 1; 6( 1): 97– 105.
- Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population. JAMA. 2002 May 15; 287( 19): 2519– 27.
- Young BA, Maynard C, Boyko EJ. Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. Diabetes Care. 2003 Aug; 26( 8): 2392– 9.
- Young BA, Rudser K, Kestenbaum B, Seliger SL, Andress D, Boyko EJ. Racial and ethnic differences in incident myocardial infarction in end-stage renal disease patients: The USRDS. Kidney Int. 2006 May 1; 69( 9): 1691– 8.
- Ito K, Bick AG, Flannick J, Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ Res. 2014 Feb 28; 114( 5): 845– 50.
- Freedman BI, Langefeld CD, Lu L, APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes. Kidney Int. 2015 Jan; 87( 1): 176– 81.
- Mukamal KJ, Tremaglio J, Friedman DJ, APOL1 Genotype, Kidney and Cardiovascular Disease, and Death in Older Adults. Arterioscler Thromb Vasc Biol. 2016 Feb; 36( 2): 398– 403.
- Weiner DE, Tighiouart H, Amin MG, Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004 May; 15( 5): 1307– 15.
-
Appel
LJ,
Wright
JT
Jr , Greene T, et al.; African American Study of Kidney Disease and Hypertension Collaborative Research Group. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med. 2008 Apr 28; 168( 8): 832– 9. -
Alves
TP,
Wang
X,
Wright
JT
Jr , Rate of ESRD exceeds mortality among African Americans with hypertensive nephrosclerosis. J Am Soc Nephrol. 2010 Aug; 21( 8): 1361– 9. - Langefeld CD, Divers J, Pajewski NM, Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial. Kidney Int. 2015 Jan; 87( 1): 169– 75.
- Reeves-Daniel AM, Depalma JA, Bleyer AJ, The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant. 2011 May; 11( 5): 1025– 30.
- Freedman BI, Julian BA, Pastan SO, Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure. Am J Transplant. 2015 Jun; 15( 6): 1615– 22.
- Freedman BI, Pastan SO, Israni AK, APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors. Transplantation. 2016 Jan; 100( 1): 194– 202.
- Bruggeman LA, O'Toole JF, Ross MD, Plasma apolipoprotein L1 levels do not correlate with CKD. J Am Soc Nephrol. 2014 Mar; 25( 3): 634– 44.
- Madhavan SM, O'Toole JF, Konieczkowski M, Ganesan S, Bruggeman LA, Sedor JR. APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol. 2011 Nov; 22( 11): 2119– 28.
- Ma L, Shelness GS, Snipes JA, Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines. J Am Soc Nephrol. 2015 Feb; 26( 2): 339– 48.
DOI: https://doi.org/10.14797/mdcj-12-4s1-2 | Journal eISSN: 1947-6108
Language: English
Page range: 2 - 5
Published on: Dec 1, 2016
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2016 Todd W. Robinson, Barry I. Freedman, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.